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Carboxyl-terminal modulator 
protein regulates Akt signaling 
during skeletal muscle atrophy 
in vitro and a mouse model of 
amyotrophic lateral sclerosis
Junmei Wang1, Colin M. e. Fry2 & Chandler L. Walker  1,2,3
Amyotrophic lateral sclerosis (ALs) is a progressive neuromuscular disease involving motor neuron 
death, paralysis and, ultimately, respiratory failure. Motor neuron dysfunction leads to target 
skeletal muscle atrophy involving dysregulation of downstream cell survival, growth and metabolic 
signaling. Decreased Akt activity is linked to muscle atrophy in ALs and is associated with increased 
atrophy gene expression. Unfortunately, the regulating mechanism of Akt activity in atrophic muscle 
remains unclear. Recent research indicates a role of carboxyl-terminal modulator protein (CtMp) in 
Akt-signaling related neurologic dysfunction and skeletal muscle metabolism. CtMp is known to 
bind and reduce Akt phosphorylation and activation. We hypothesized that CtMp expression might 
progressively increase in ALs skeletal muscle as the disease progresses, downregulating Akt activity. 
We found that CTMP protein expression significantly increased in hindlimb skeletal muscle in the 
mSOD1G93A mouse model of ALs in late stages of the disease (P < 0.05), which negatively correlated 
with Akt phosphorylation over this period (R2 = −0.77). Co-immunoprecipitation of Akt revealed CTMP 
binding in pre-symptomatic and end-stage skeletal muscle, suggesting a possible direct role in reduced 
Akt signaling during disease progression. Inflammatory TNFα and downstream cellular degradation 
process markers for autophagy, lysosome production, and atrophy significantly increased in a pattern 
corresponding to increased CtMp expression and reduced Akt phosphorylation. In an in vitro model 
of skeletal muscle atrophy, differentiated C2C12 cells exhibited reduced Akt activity and decreased 
FOXO1 phosphorylation, a process known to promote transcription of atrophy genes in skeletal muscle. 
these results corresponded with  increased  Atrogin-1 expression  compared to healthy control cells  
(P < 0.05). Transfection with CTMP siRNA significantly increased Akt phosphorylation in atrophic C2C12 
cells, corresponding to significantly decreased CTMP expression. In conclusion, this is the first study to 
provide evidence for a link between elevated CtMp expression, downregulated Akt phosphorylation 
and muscle atrophy in ALS and clearly demonstrates a direct influence of CTMP on Akt phosphorylation 
in an in vitro muscle cell atrophy model.
Motor neuron diseases (MND) are a collection of neurological disorders that affect upper and lower motor neu-
rons of the central nervous system (CNS). The most common form of MND is amyotrophic lateral sclerosis 
(ALS), which affects individuals at primary productive periods of life and afflicts both upper and lower motor 
neurons1–3. ALS is diagnosed by excluding other possible conditions, and once identified, has typically progressed 
to advanced stages and prognosis is 3–5 years. No cures for ALS exist and approved therapies have marginal 
effects on disease progression and survival. A major contributor to the difficulty of identifying and developing 
effective treatments, aside from delayed diagnosis, is the complex non-cell autonomous nature of the disease. 
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Astrocytes and microglia influence motor neuron survival and health in the CNS, while neuromuscular inter-
actions in the periphery also play a role in disease progression. Targeting multiple cell types and influences of 
disease onset and progression is difficult, and our understanding of the many factors contributing to ALS remains 
incomplete.
Much research to date has focused on improving motor neuron survival as a means to improve functional 
outcomes and slow disease progression; however, due to the dynamic nature of the disease and involvement of 
various cells and structures, this approach has not proven effective. In the past two decades, our understanding of 
the pre-symptomatic aspects of disease progression have expanded considerably, and we know that some of the 
first major outward pre-symptomatic anatomic manifestations of disease is the dismantling of the neuromuscular 
junction (NMJ) and progressive disconnection of motor neurons from NMJs4–7. With this information, further 
insights into physiologic changes within the skeletal muscle over time in humans and ALS animal models, espe-
cially the classic mutant superoxide dismutase 1 (SOD1) mouse model (mSOD1G93A)8, have been made possible.
As a result of reduced motor stimulation in ALS progression, skeletal muscles atrophy and multiple biochem-
ical processes in skeletal muscle cells have been implicated in this process. Since skeletal muscle is peripheral and 
directly affected early in ALS progression5,6,9–11, assessment of biochemical changes in animal models and human 
ALS for identification of potential markers of disease has increased in interest. Recent research indicated that a 
reduction in insulin signaling and expression and activity the serine-threonine kinase, Akt, are associated with 
progressive muscular atrophy in animal models and correlated with poor survival prognosis in ALS patients12–14. 
Reduced Akt can be correlated with high expression of autophagosome and lysosomal markers through sub-
sequent effects on downstream effectors including the mammalian target of rapamycin (mTOR)15,16, and these 
changes have also been linked to muscle atrophy17. Reduced autophagic flux, or increased autophagosome aggre-
gation and lysosome formation have been demonstrated in advanced mSOD1G93A mouse skeletal muscle17. Active 
Akt can also phosphorylate forkhead box (FOXO) proteins, including FOXO1, which prevents them from enter-
ing the nucleus and promoting transcription of atrophy genes such as Atrogin1 (MAfbx) and muscle-ring finger-1 
(MuRF-1), and thus the expression of these E3-ubiquitin ligases in muscle cells18,19. Therefore, downregulation of 
Akt activity promotes atrophy-associated protein expression and increases muscle degradation processes through 
such mechanisms.
Akt is activated by phosphorylation at multiple sites through phosphatidylinositol-3-kinase signaling, and 
binding of carboxyl-terminal modulator protein (CTMP) can prohibit this activation20. CTMP is upregulated 
in neurological disorders such as stroke and traumatic brain injury, and its inhibition increased Akt phospho-
rylation and signaling and reduced neurological tissue damage21–23. Akt activation is linked to myogenesis and 
atrophy, with its activity increasing and decreasing, respectively. Only recently has the role of CTMP been tied to 
muscle metabolism, with a reduction in CTMP causing upregulation of Akt phosphorylation and increased myo-
genesis24. Here we report key biochemical changes in the gastrocnemius muscle of the mSOD1G93A amyotrophic 
mouse model and discuss for the first time, a potential association between CTMP and Akt activation overtime 
in the muscle of this mouse model.
Results
Akt phosphorylation and CtMp expression are inversely correlated, and Akt and CtMp interact 
in mSOD1G93A muscle. To assess temporal changes in Akt phosphorylation in progressively denervated and 
atrophying mSOD1G93A mouse skeletal muscle, gastrocnemius protein from post-natal day (PD)35 (pre-dener-
vation), PD63 (pre-symptomatic), PD90 (near symptom onset) and end-stage was collected and phosphorylated 
and total Akt were assessed via Western blot (Fig. 1). As measured as a ratio of phosphorylated Akt to total 
Akt, Akt phosphorylation showed significant upregulation by PD63 compared to PD35 (P < 0.001) (Fig. 1A,D). 
Activity was then significantly reduced by PD90 compared to both PD35 and PD63 (both P < 0.001). At end-
stage, Akt phosphorylation remained similar to the level observed at PD90 (Fig. 1A,D).
CTMP expression in this muscle tissue exhibited a near opposite expression pattern over time compared to 
Akt phosphorylation. Though CTMP expression remained unchanged between PD35 and PD63, its expression 
significantly increased by PD90 compared to both PD35 (P < 0.01) and PD63 (P < 0.05) (Fig. 1B,D). CTMP 
expression remained significantly elevated at end-stage compared to these earlier timepoints (P < 0.05), though 
its expression level was similar to that observed at PD90 (Fig. 1B,D). Regression analysis showed a very high 
inverse linear correlation between Akt phosphorylation and CTMP expression over time (R2 = −0.77) (Fig. 1C). 
Immunoprecipitation of Akt in pre-symptomatic mSOD1G93A muscle and end-stage atrophic muscle from this 
mouse model showed binding of CTMP to Akt (Fig. 1E), corresponding to the increased expression of these pro-
teins over time. This provides evidence that the correlation of CTMP increase and Akt phosphorylation may be 
due to CTMP binding-induced inhibition. In comparison to wild-type mouse gastrocnemius tissue, CTMP was 
qualitatively upregulated in end-stage mSOD1G93A as observed via immunofluorescence labeling (Fig. 2).
Inflammation and degradation pathways are upregulated in atrophying mSOD1G93A muscle. 
Inflammation is a common characteristic of progressive muscle atrophy25–27, and E3 ubiquitin ligase MuRF-1 
protein is known to be increased in late-stage mSOD1G93A skeletal muscle11 and related to inflammation-induced 
muscle atrophy28. We found that TNFα levels gradually increased and were significantly higher at end-stage than 
early in the disease (PD35, P < 0.05, Fig. 3A,D). In looking at downstream cell degradation pathways associated 
with skeletal muscle break-down and Akt signaling, autophagosome flux, as indicated by the expression ratio 
of LC3 II to I, was increased by PD90 compared to earlier pre-symptomatic timepoints (P < 0.05, Fig. 3B,D). In 
addition, lysosome increase, as indicated through LAMP1 expression, was also significantly increased at PD90 
compared to PD63 (P < 0.05) and PD35 (P < 0.05, Fig. 3C,D). Regarding muscle atrophy, our findings confirmed 
a significant upregulation of MuRF-1 over time in mSOD1G93A gastrocnemius muscle (P < 0.05, Fig. 3E).
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An in vitro model of muscle atrophy shows increased CtMp expression and reduced Akt phos-
phorylation. To investigate whether CTMP and Akt signaling were influenced in a similar way observed 
in late-stage mSOD1G93A mouse gastrocnemius, we performed Western blot analysis. We found that Akt phos-
phorylation was significantly reduced 24 hours following TNFα treatment in differentiated C2C12 myotubes 
(P < 0.05, Fig. 4A,E). The expression of PTEN, a known suppressor of Akt activity, was downregulated in these 
cells (P < 0.05, Fig. 4B,E), suggesting it was not a likely factor in Akt phosphorylation reduction. Meanwhile, 
CTMP expression was significantly increased (P < 0.05, Fig. 4C,E), as observed in late-stage ALS mouse muscle. 
Figure 1. Changes in Akt signaling and CTMP expression, and their interaction during disease progression 
in mSOD1G93A muscle. Akt phosphorylation significantly decreased by post-natal day (PD) 90 (A,D), while 
CTMP increased during this period (B,D). This relationship is inversely correlated throughout end-stage 
(~PD130) (C). CTMP exhibited considerable binding to Akt at end-stage compared to PD35, correlating with 
their respective expression levels at these time points, as shown via co-immunoprecipitation (E). This supports 
CTMP binding to Akt as a mechanism of Akt phosphorylation downregulation in mSOD1G93A muscle. Blot 
images are cropped from different membranes used for data collection and analysis (See Supplemental Figures). 
*P < 0.05; **P < 0.01; ***P < 0.001.
Figure 2. Immunofluorescence labeling of CTMP supports dramatic end-stage expression differences in WT 
and mSOD1G93A gastrocnemius muscle. This image represents a longitudinal section through WT and end-stage 
mSOD1G93A mouse gastrocnemius muscle. A notable increase in CTMP expression (green) observed in end-
stage muscle tissue compared to muscle from WT mice. Red represents MHC IIb/x immunostaining for muscle 
fibers, and blue is Hoechst 33342 labeling of cell nuclei. Scale bar = 100 μm.
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Figure 3. Inflammation, cell degradation markers and atrophy increase over time in mSOD1G93A hindlimb 
muscle. TNFα increases over time in mSOD1G93A gastrocnemius muscle tissue (A,D), as well as autophagosome 
(B,D) and lysosomal aggregation (C,D). The E3 ubiquitin ligase, MuRF-1 is significantly increased at PD90 
compared to PD35, indicating increased muscle breakdown and atrophy as the disease progresses (E). Blot 
images are cropped from different membranes used for data collection and analysis (See Supplemental Figures). 
*P < 0.05.
Figure 4. Treating differentiated murine C2C12 myotubes with 100 ng/mL TNFα for 24 hrs induced similar 
intracellular signaling pathway changes as observed in late-stage mSOD1G93A mouse muscle tissue. Akt 
phosphorylation decreased following TNFα treatment (A,E). Meanwhile, PTEN expression was downregulated, 
suggesting it may not be a key modulator of Akt phosphorylation (B,E). However, CTMP expression 
significantly increased (C,E), as seen in the ALS mouse muscle. FOXO1 phosphorylation decreased (D,E), 
allowing it to permit transcription of atrophy genes such as Atrogin-1, which was significantly upregulated (F). 
Blot images are cropped from different membranes used for data collection and analysis (See Supplemental 
Figures). *P < 0.01; ***P < 0.001.
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Reduced Akt signaling causes reduced FOXO1 phosphorylation, which enables its function of entering the 
nucleus to promote atrophy gene expression. Accordingly, we found FOXO1 phosphorylation was significantly 
decreased (P < 0.05, Fig. 4D,E). RT-PCR confirmed upregulation of Atrogin-1 gene expression (P < 0.05, Fig. 4F), 
further corroborating our in vivo findings.
CtMp knock-down rescues Akt phosphorylation in vitro. Using the TNFα treated C2C12 cell model 
of muscle atrophy, we then tested whether knock-down of CTMP could increase Akt phosphorylation and con-
firm a direct relationship between CTMP and Akt signaling in atrophic muscle. After knocking down CTMP 
expression with CTMP-targeted siRNA, the significant decrease in CTMP expression (P < 0.05) corresponded 
with a significant increase of Akt phosphorylation compared with non-transfected control cells (P < 0.05) (Fig. 5).
Discussion
This study is the first to show a direct connection between the expression of CTMP and downregulation of Akt 
phosphorylation in atrophic muscle. Importantly, this is also the first work to provide a potential mechanism for 
the downregulation of Akt activity in late-stage ALS mouse muscle, portraying it as a potential target. A neuro-
centric focus of ALS has long guided research and therapeutic investigation, though systemic influences have 
gained increasing attention as major contributors to onset and progression of the disease. Of these, target skeletal 
muscle, which is directly linked to motor dysfunction and paralysis, has been one of the most widely studied 
tissues. Much evidence suggests at least in mSOD1G93A mutation-associated ALS, many pathologic changes in 
target skeletal muscle occur before symptom onset and motor neuron loss. In the mSOD1G93A mouse model, a 
decrease in hindlimb muscle fiber size is noticeable between postnatal weeks eight & nine29, which follows closely 
after initial significant muscle denervation in this muscle group5,6. Early neuromuscular denervation triggers 
compensatory sprouting of motor axons, and ultimately, progresses toward disconnection from skeletal muscle. 
Several studies have investigated the cellular mechanisms that are characteristic of denervated skeletal muscle, 
particularly with regard to metabolic and cellular degradation pathways linked to progressive muscle atrophy30,31. 
As a primary pro-survival and key cell metabolism signaling kinase, reduced Akt phosphorylation and activity 
have been documented in symptomatic human and rodent ALS model skeletal muscle. We demonstrate here 
that skeletal muscle Akt phosphorylation significantly decreases over time in the mSOD1G93A mouse model, with 
relatively increased levels at pre-symptomatic stages and significant downregulation approaching symptom onset.
Sustaining muscle mass depends heavily on innervation and neural stimulation of NMJs. As mentioned, 
hindlimb skeletal muscle is significantly denervated by post-natal day 47 in the mSOD1G93A mouse5,6, and our 
findings in the present study indicate that Akt signaling and cell degradation-associated processes including 
autophagosome and lysosome aggregation and increased muscle atrophy are low during and through this period. 
However, these processes, as indicated by LC3 lipidation, LAMP-1 and MuRF-1 expression, respectively, signifi-
cantly increase at later stages of disease when Akt signaling is greatly decreased. Others have observed increased 
Akt expression, as well as elevated Akt phosphorylation in skeletal muscle of mSOD1G93A mice beginning in 
a pre-symptomatic stage of disease corresponding to our PD63 time point and continuing until end-stage32. 
However, this research group still observed muscle atrophy over the lifespan of the mice. One difference in their 
study and the present report is that they utilized a pool of different hindlimb muscles for protein analysis of 
Akt expression and phosphorylation, while we used only the medial gastrocnemius muscle. Different muscles 
are denervated at different rates in the mSOD1G93A mouse based on the fiber-type content of a given muscle33. 
Motor axons with increased metabolic burden are the first to disconnect from NMJs5, and muscle fibers shown 
through electromyography to exhibit early motor dysfunction representative of denervation are fast twitch muscle 
fibers33. Medial gastrocnemius contains fast and slow twitch muscle fibers, and the fast twitch fibers are the first 
to undergo denervation, while some slower action muscle fibers maintain innervation33. Therefore, the use of 
Figure 5. Knocking down CTMP in TNFα-treated differentiated C2C12 myotubes using siRNA rescued the 
decrease in Akt phosphorylation. Incubating differentiated TNFα-treated C2C12 myotubes with siRNA against 
CTMP for 73 hours significantly decreased CTMP expression and increased Akt phosphorylation, indicating 
a direct relationship between CTMP expression and Akt phosphorylation in this muscle atrophy model. Blot 
images are cropped from different membranes used for data collection and analysis (See Supplemental Figures). 
*P < 0.05.
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pooled hindlimb muscles may include a disproportionate number of fast versus slow fibers, and may have differ-
ent intracellular functions based on state of innervation leading to the increased Akt and its phosphorylation as 
the disease progresses in the mSOD1G93A mouse32.
A detailed study showed that atrophy of the gastrocnemius muscle is observed shortly after the docu-
mented initial denervation period of 40–50 days of age in the mSODG93A mouse, and that it corresponds with 
onset of muscular dysfunction34. This evidence suggests, at least in the case of the medial gastrocnemius, that 
pre-symptomatic denervation may trigger early muscle atrophy. Interestingly, following post-natal day 47, com-
pensatory collateral sprouting of motor axons to reinnervate disconnected NMJs occurs, and mice show no out-
ward physical symptoms until closer to 100 days of age, though some minor motor deficits occur as early as 
post-natal day 5534. Still, this compensatory reinnervation may stimulate muscle metabolism and increased Akt 
signaling in middle pre-symptomatic stages of disease. This could explain why we observed significantly increased 
Akt phosphorylation at post-natal day 63 compared to day 35. Unfortunately, this sprouting and reinnervation 
diminishes over time and eventually a threshold level of NMJ denervation occurs, corresponding to reduced 
motor neuron numbers and contributing to progressive muscle dysfunction and increased muscle atrophy35. As 
shown here, by 90 days of age, the mice exhibit significantly decreased levels of Akt phosphorylation compared 
to day 63, and this low level is sustained through end-stage. One mechanism of NMJ denervation-mediated 
influence on muscle atrophy involves feedback inhibition of insulin signaling and subsequent downregulation of 
Akt phosphorylation36. Through this mechanism,  mammalian target of rapamycin (mTOR) and downstream S6 
kinase activity feedback and inhibit this signaling pathway, which promotes upregulation of FOXO nuclear trans-
location and increased atrophy gene transcription. This is counterintuitive to the common understanding of the 
regulation of such processes by Akt and downstream signaling through mTOR37–39. However, this mechanism is 
sensible in the temporal context of muscle atrophy observed in ALS, with humans and rodents exhibiting reduced 
muscle function and significant muscle atrophy as the disease progresses29,40,41.
Although most studies concerning catabolic mechanisms contributing to muscle wasting in ALS have focused 
downstream of Akt, few studies have investigated the potential intracellular causes of Akt activity downregula-
tion. We found a linear relationship between increased CTMP expression and reduced Akt phosphorylation in 
progressively atrophying mSOD1G93A muscle. Since CTMP-mediated inhibition of Akt is dependent on its bind-
ing to Akt and preventing it from targeting the plasma membrane20, we immunoprecipitated Akt and found that 
it bound to CTMP  at a low level at the early-pre-symptomatic timepoint of PD35, indicative of its low expression 
at this point in time as shown in Fig. 1. However, at end-stage, when CTMP expression was significantly elevated, 
its binding to immunoprecipitated Akt was markedly increased. This is the first evidence showing a temporal rela-
tionship between Akt and CTMP, and confirming their interaction to potentially explain the linear inverse rela-
tionship between CTMP expression and Akt phosphorylation in progressively atrophying mSOD1G93A muscle.
To more clearly assess the mechanisms associated with muscle atrophy, we utilized an established 
TNFα-induced C2C12 myotube atrophy model and examined Akt phosphorylation, CTMP expression, and 
related signaling processes. As reported by Wang et al.42, TNFα caused a significant downregulation of Akt phos-
phorylation in these cells. As anticipated, we also observed a subsequent downregulation of FOXO-1 phosphoryl-
ation associated with increased Atrogin-1 expression. As seen in atrophic muscle in our ALS mouse model, CTMP 
expression also increased, which has not been reported. This increase in CTMP concomitant with downregulated 
Akt phosphorylation suggested the two could be associated. To examine whether PTEN could have been involved 
in the downregulation of Akt phosphorylation, we examined PTEN expression through Western blot analysis. 
Surprisingly, PTEN expression significantly decreased after TNFα treatment in the differentiated C2C12 cells, 
suggesting it was not likely responsible for Akt phosphorylation downregulation. Likewise, it further supported 
our hypothesis that CTMP played a role in reduced activity of Akt.
To confirm whether CTMP significantly influenced Akt phosphorylation in our in vitro model of muscle 
atrophy, knock-down of CTMP with specific siRNA resulted in an expected significant decrease in CTMP expres-
sion, but also significantly increased Akt phosphorylation. To our knowledge, this is the first evidence of CTMP 
modulating Akt phosphorylation in skeletal muscle atrophy. As Akt has been so widely studied in muscle atrophy 
in various conditions and diseases, this raises the question as to whether CTMP could be a common negative 
regulator of Akt activity and its downstream signaling, contributing to catabolic and atrophy processes in skeletal 
muscle. Not only is CTMP a potential target for therapy in neurologic injury, but also in skeletal muscle atrophy. 
Though we did not see increased CTMP upregulation early in the disease process in ALS mouse model muscle 
tissue, its expression pattern was similar to the observed increase in MuRF-1 expression between PD35 and PD90. 
As such, CTMP may still be exerting its negative influence on Akt activity leading to muscle atrophy, with its 
increased expression exacerbating the process over time.
Despite our results, the present study has some limitations and notable issues. First, the transition between 
PD63 and PD90 appears to be a critical period in the shift in metabolic processes and associated cell signaling. 
Future research examining skeletal muscle in the mSOD1G93A mouse model at individual points during this time 
period could reveal interesting and important details concerning cell signaling involvement in the disease pro-
cess. Though hindlimb muscle denervation significantly decreases several weeks earlier than symptom onset in 
the hindlimb muscles of this mouse model, transient compensatory sprouting occurs allowing for continued nor-
mal outward function of the muscle in the locomotion and ambulatory activities of the mouse43–45, as symptoms 
are not typically observed until near 100 days of age46. Also, the comparison of the effects of triggered muscle 
atrophy processes in a muscle cell line is not as optimal as proof from primary cell culture. Additional research 
into the biochemical processes primary skeletal muscle cells from mSOD1G93A and WT control mice will allow for 
a more accurate perspective on the mechanistic role of CTMP in skeletal muscle cells under normal and atrophic 
conditions. Lastly, a correlation between our findings in the mSOD1G93A mouse with human ALS patient muscle 
tissue would help anticipate the translational potential for any developed therapies.
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In conclusion, this study sheds new light on the regulation of Akt phosphorylation in mSOD1G93A mouse 
muscle by CTMP and provides evidence that it plays a direct role in the consistently observed reduction in the 
activity of Akt and its downstream biochemical processes in atrophic muscle (Fig. 6). There are several reports of 
a negative role for CTMP in neuronal survival via reduced Akt signaling in neurological research, and this study 
suggests it could be a potential target in one of the earliest pathologies documented in ALS. Future research will 
more clearly elucidate the role of CTMP and the effects of limiting its inhibitory influence on Akt in ALS and 
other neuromuscular disorders.
Methods
Mouse muscle collection and biochemical preparation. Wild-type (WT) and 35d, 63d, 90d B6SJL 
mSOD1G93A mice (Jackson Mice, Bar Harbor, ME) (n = 3–4 per group) were sacrificed via ketamine/xylazine 
and followed by rapid removal and flash freezing of gastrocnemius muscle tissue. To isolate protein, the muscle 
was minced and placed in radioimmunoprecipitation assay (RIPA) buffer with Halt protease and phosphatase 
inhibitor cocktail (Thermo Pierce). The minced muscle tissue in lysis buffer was then homogenized and left on 
ice for 30 min for additional lysis. Next, the lysed muscle tissue tubes were centrifuged at 13,000 rpm for 10 min-
utes to pellet non-digested debris and tissue. The supernatant was carefully removed, and concentrations of each 
sample was determined using a bicinchoninic acid (BCA) assay. All animal procedures were approved by the 
Institutional Animal Care and Use Committee of the Indiana University School of Dentistry and followed the 
National Institutes of Health (NIH) Guidelines on the humane care and use of laboratory animals.
C2C12 myoblast culture, differentiation and CTMP knock-down. To test whether CTMP 
knock-down affects Akt phosphorylation in an in vitro model of muscle atrophy, C2C12 myoblasts (ATCC) 
were cultured in 6 well plates at a density of 4 × 105 cells/well for 24 hrs in normal growth medium (Dulbecco’s 
Modified Eagle Medium [DMEM] supplemented with 10% fetal bovine serum [FBS] and 1% penicillin/strepto-
mycin [P/S], Life Technologies, Inc. Carlsbad, CA). Upon reaching 90% confluency, the normal growth medium 
was removed, and cells were treated with 50 nM CTMP siRNA or 50 nM scrambled non-targeting siRNA in 
proprietary siRNA Transfection Medium (Santa Cruz Biotechnologies) for 5 hours. Then, 1 mL normal growth 
medium was added for an additional 24 hours. The next day, normal growth medium was removed, the cells were 
washed in DMEM and then incubated in differentiation medium (DMEM + 2% FBS + 1% P/S) for 72 hours. After 
this period, myotubes were prominent indicating differentiation, and 100 ng/mL TNFα was added in DMEM for 
24 hrs to induce an atrophic state as described by Wang et al.42. Whole cell lysates of each sample were then pre-
pared in 1x Laemmli buffer (Bio-Rad) with 5% β-mercaptoethanol for Western blot analysis. Experiments were 
repeated in triplicate.
Western blot. Western blot data was performed as described previously47. In brief, 20–30 μg protein was 
loaded onto 4–20% gradient tris-glycine gels (TGX, Bio-Rad) and the protein was transferred onto polyvinyli-
dinefluoride (PVDF) membranes via a TransBlot machine (Bio-Rad). Following a wash in phosphate buffered 
saline (PBS), the membranes were blocked in milk blocking buffer (ThermoPierce) for 1 hour at room temper-
ature. Then, the membranes were incubated with the following primary antibodies in PBS + 0.1% Tween 20 
(PBST) + milk blocking buffer (ThermoPierce) overnight at 4 °C or 1 hr at room temperature: mouse anti-pan 
Akt, rabbit anti-p-AktSer473, rabbit anti-LAMP1 (1:1,000), a marker for lysosomal activation, TNFα (1:1,000), 
Figure 6. Schematic diagram for the proposed mechanism of CTMP-mediated Akt activity decrease and 
downstream signaling modulation in progressive muscle atrophy. The present study provides evidence that 
increased CTMP in atrophying mSOD1G93A skeletal muscle correlates with Akt inactivation. The regulation of Akt 
signaling by CTMP may be due to binding of Akt and preventing its activation at the plasma membrane, leading to 
downstream increased expression in pro-atrophy genes and proteins, including Atrogin-1 and MuRF-1.
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rabbit anti-CTMP (1:1,000) (Cell Signaling Inc.), rabbit anti-LC3 (1:500; Abcam), a marker of autophagosome 
flux, rabbit anti-MURF-1, a marker of atrophy (1:1000, EMC Biosciences), and mouse anti-β-tubulin (Cell 
Signaling Inc.) and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Sigma-Aldrich) were 
used as loading controls. Following primary antibody incubation, the membranes were washed 3x with PBST 
and incubated with either Li-Cor IRdye 600 or 800 for imaging on a Li-Cor Odyssey Fc machine, or horserad-
ish peroxidase (HRP)-conjugated secondary antibodies for use in enhanced chemiluminescence (ECL) imaging 
using a Li-Cor c-DiGit imaging system (Li-Cor). After secondary antibody incubation and washes with PBST, 
IRDye-incubated membranes were immediately imaged. Those incubated with HRP-conjugated secondary 
antibodies were exposed to ECL reagents (ThermoPierce ECL Kit, ThermoPierce; Western Sure Premium ECL, 
Li-Cor) for 1–5 min. Excess ECL reagent was blotted off of the membranes and they were imaged as described 
above. Resulting bands were converted to gray scale and densitometry analysis was performed using ImageJ 
software (NIH).
Co-immunoprecipitation of Akt and CtMp. Co-immunoprecipitation of Akt total protein and bound 
CTMP from mSOD1G93A gastrocnemius muscle followed previously published protocols with modification 
(Wu et al., 2017). In brief, Bio-Rad Rapid Magnetic Beads (Bio-Rad) were used to bind pan-Akt antibody (Cell 
Signaling, 1:50) and this complex was allowed to immunoreact with PD35 and end-stage mSOD1G93A mouse 
gastrocnemius muscle protein lysate under rotation for 1 hr at room temperature. Non-antibody protein exposure 
(beads only) was used as a negative control. The bound protein was eluted for Western blotting via addition of 1x 
Laemmli sample buffer (Bio-Rad) and heating at 70 °C for 10 min. After heating, the sample buffer containing the 
immunoprecipitated and associated proteins was transferred to a separate tube for Western blot.
primers. Primers for real-time PCR were as follows (sense and antisense, 5′ to 3′): Atrogin-1/Mafbx: TGAAT 
AGCATCCAGATCAGCA, GATGTTCAGTTGTAAGCACACAG; GAPDH: AATGGTGAAGGTCGGTGTG, 
GTGGAGTCATACTGGAACATGTAG (PrimeTime qPCR Primers, IDT, Coralville, IA).
RNA Isolation and Real-Time PCR. Total RNA was isolated from differentiated C2C12 cells and reverse 
transcription (RT) and qPCR were performed to assess atrophy gene expression (PureLink RNA Isolation Kit, 
Invitrogen, Carlsbad, CA). Total isolated RNA was reverse transcribed using a High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) and a Bio-Rad C1000 thermal cycler (Hercules, CA) 
according to the manufacturer’s instructions. Real-time PCR was performed in an ABI Prism 7000 system 
(Applied Biosystems) using the obtained complementary DNA and a Maxima SYBR Green/ROX qPCR kit 
(ThermoPierce). GAPDH was used as an internal control.
CTMP Immunofluorescence Labeling. For muscle tissue collection and immunofluorescence labeling, 
previously published methods were used6. In brief, end-stage wild-type (WT) and mSOD1G93A mice (n = 3/
group) were sacrificed using ketamine/xylazine, and perfused with 0.1 M phosphate buffered saline (PBS) fol-
lowed by 4% paraformaldehyde solution in PBS to fix the tissue. The medial gastrocnemius was dissected and 
placed in the same fixative for 30 minutes at 4 °C. The muscle tissue was then washed with PBS and placed in 30% 
sucrose in PBS for cryopreservation overnight at 4 °C. After cryopreservation, the muscle tissue was embedded 
in TissueTek OCT media and serially sectioned longitudinally at 20 μm using a cryostat (Leica) and mounted on 
SuperFrost Plus microscope slides (Fisher Scientific). Four muscle sections at 200 μm intervals were selected for 
labeling per mouse. For immunofluorescence labeling of the muscle for CTMP, the tissue was permeabilized in 
PBS + 0.1% Triton-X 100 (PBST, Fisher Scientific) and blocked for non-specific labeling using 10% normal goat 
serum in PBST (blocking buffer) for 1 hr at room temperature. Then, the slides were incubated in blocking buffer 
with rabbit anti-THEM4 (CTMP) antibody (1:100, Abcam) and combined muscle fiber type antibodies, mouse 
anti-myosin heavy chain IIb and IIx (MHC IIb/x) (1:50, Developmental Studies Hybridoma Bank, University of 
Iowa) for 1 hr at room temperature. Next, the slides were washed and incubated in AlexaFluor-conjugated goat 
anti-rabbit and goat anti-mouse secondary antibody (1:200, Jackson Immunoresearch) and Hoechst 33342, for 
labeling nuclei (5 μg/mL, Sigma-Aldrich) for 1 hr at room temperature. The sections were then washed and cov-
erslipped in Anti-Fade Gold aqueous mounting media (Life Technologies, Inc.) and left to dry before imaging. 
Imaging was performed on a Nikon epifluorescent microscope.
statistical analysis. All values are presented as mean +/−SEM. Comparisons between three or more groups 
was performed using a one-way ANOVA with Newman-Keuls post-hoc analysis if significance was determined. 
Comparisons between two groups were made using an unpaired t-test. All statistical analysis and graphing were 
completed using GraphPad Prism 6.0 software (GraphPad, Inc). p < 0.05 was considered statistically significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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